(Q51328925)

English

Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study.

scientific article published on 12 February 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24400655

Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study. (English)

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24400655

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

author name string

R E Pratley

1

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24400655

P Fleck

2

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24400655

C Wilson

3

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24400655

publication date

12 February 2014

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24400655

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24400655

16

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24400655

7

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24400655

613-621

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24400655

AACE comprehensive diabetes management algorithm 2013.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12258

21 January 2018

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12258

21 January 2018

Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12258

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12258

21 January 2018

Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12258

21 January 2018

Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12258

21 January 2018

Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12258

21 January 2018

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12258

21 January 2018

Metformin + saxagliptin for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12258

21 January 2018

Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12258

21 January 2018

Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12258

21 January 2018

Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12258

21 January 2018

Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12258

21 January 2018

New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12258

21 January 2018

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12258

21 January 2018

Metformin: new understandings, new uses

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12258

21 January 2018

Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12258

21 January 2018

Identifiers

10.1111/DOM.12258

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24400655

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24400655

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51328925&oldid=1314986740"